T1	outcome 1577 1595	secondary leukemia
T2	outcome 1503 1534	died as a result of dysrhythmia
T3	outcome 1352 1396	decreased left ventricular ejection fraction
T4	outcome 1163 1177	acute toxicity
T5	outcome 1200 1219	grade 2 neutropenia
T6	outcome 1229 1243	grade 2 anemia
T7	outcome 1253 1279	grade 3 nausea or vomiting
T8	outcome 1293 1309	grade 3 alopecia
T9	outcome 1091 1101	Compliance
T10	outcome 795 805	6-year DFS
T11	total-participants 476 479	338
T12	control-participants 571 574	164
T13	intervention-participants 683 686	174
T14	age 360 379	older than 65 years
T15	eligibility 381 428	with node-positive, operable breast cancer (BC)
T17	intervention 42 67	epirubicin plus tamoxifen
T16	control 75 90	tamoxifen alone
T18	cv-bin-percent 817 822	69.3%
T19	iv-bin-percent 836 841	72.6%
T20	outcome 909 924	risk of relapse
T24	cv-bin-percent 1050 1055	79.1%
T25	iv-bin-percent 1060 1065	79.8%
T21	outcome 1003 1012	6-year OS
